Trial Profile
An Open-label Single-arm Multicentre Non-controlled Phase 3a Trial Investigating Safety and Efficacy of N8-GP in Prophylaxis and Treatment of Bleeding Episodes in Previously Untreated Paediatric Patients With Severe Haemophilia A
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2023
Price :
$35
*
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Adverse reactions; Registrational
- Acronyms pathfinder™6
- Sponsors Novo Nordisk
- 17 Aug 2023 Status changed from active, no longer recruiting to completed according to result published in the Journal of Thrombosis and Haemostasis
- 17 Aug 2023 Pathfinder6 end-of-trial results published in the Journal of Thrombosis and Haemostasis.
- 13 Dec 2022 Results assessing the immunogenicity, safety and efficacy of N8-GP in PUPs with severe hemophilia A, presented at the 64th American Society of Hematology Annual Meeting and Exposition.